Clinical Research Directory

Inclusion Criteria * Has a histologically confirmed diagnosis of unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC). * Has measurable disease per RECIST 1.1. * Has adequate organ function. * Has adequately controlled blood pressure (BP). * If participants received major surgery or radiation therapy of \>30 Gy, they must have recovered from the toxicity and/or complications from the intervention. * Has resolution of the toxic effect(s) of the most recent prior therapy. * Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks prior to allocation. * Is Chinese descent, defined as both biological parents and all biological grandparents are of Chinese descent. Male Participants: \- Must be willing to use an adequate method of contraception. Female Participants: \- Must be a woman of non-childbearing potential (WONCBP) or have a negative urine or serum pregnancy test and must be willing to use an adequate method of contraception. For Belzutifan + Lenvatinib treatment: * Has progressed on or after having received systemic treatment for locally advanced or metastatic RCC. * Has no more than 3 prior systemic regimens for locally advanced or metastatic RCC. For Belzutifan + Lenvatinib + Pembrolizumab treatment: \- Has received no prior systemic therapy for advanced RCC. Exclusion Criteria * Is a woman of childbearing potential (WOCBP) who has a positive urine pregnancy test within 24 hours prior to first dose of study intervention. * Has any of the following: A pulse oximeter reading \<92%, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen. * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. * Has known central nervous system (CNS) metastases and/or carcinomatous meningitis. * Has clinically significant cardiac disease. * Has symptomatic pleural effusion. * Has a history of inflammatory bowel disease. * Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula. * Has clinically significant hematuria, hematemesis or hemoptysis of red blood, or other history of significant bleeding within 3 months before administration of the first dose of study intervention. * Has other clinically significant disorders such as: A serious active non-healing wound/ulcer/bone fracture, requirement for hemodialysis or peritoneal dialysis or a history of allogenic tissue/solid organ transplantation. * Received colony-stimulating factors, granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant EPO within 28 days prior to the first dose of study intervention. * Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study. * Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption. * Has received prior treatment with belzutifan. * Has received prior treatment with lenvatinib. * Has received any type of systemic anticancer antibody (including investigational antibody) ≤28 days prior to allocation. * Has received / will be receiving any traditional Chinese medicines. * Has received prior radiotherapy within 2 weeks prior to first dose of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids. * Is receiving concomitant treatment, in therapeutic doses, with anticoagulants. * Is receiving chronic systemic steroids therapy (at doses \>10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention. * Is currently participating in a study of an investigational agent or is currently using an investigational device. * Has an active infection requiring systemic therapy. * Has a known history of Human Immunodeficiency Virus (HIV) infection. * Has a known history of Hepatitis B or known active Hepatitis C virus infection. * Has a known history of active tuberculosis. * Has radiographic evidence of intratumoral cavitation, encasement or invasion of a major blood vessel. * Has known hypersensitivity or allergy to the active pharmaceutical ingredient or any component of the study intervention (belzutifan or lenvatinib) formulations. * Has had major surgery within 4 weeks prior to first dose of study intervention. For Belzutifan + Lenvatinib + Pembrolizumab treatment: * Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. * Has a history of hypersensitivity reaction to the active pharmaceutical ingredient or any component of pembrolizumab or monoclonal antibody (mAb). * Has an active autoimmune disease that has required systemic treatment in the past 2 years. * Has received a live vaccine within 30 days prior to the first dose of study intervention.